{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:01:58Z","timestamp":1791846118020,"version":"4.3.4"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008840","name":"Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}],"id":[{"id":"10.13039\/501100008840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02897-w","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T16:14:49Z","timestamp":1752941689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Breaking the oncogenic link: BCL10\u2013MALT1 disruption as a precision strike against NF-\u03baB-driven lymphomas"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-9564","authenticated-orcid":false,"given":"Emadeldin M.","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally Mostafa","family":"Khadrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris F. Aba","family":"Alkhayl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Mokhtar","family":"Lamsabhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"2897_CR1","doi-asserted-by":"publisher","first-page":"1379376","DOI":"10.3389\/fimmu.2024.1379376","volume":"15","author":"MV Pereira","year":"2024","unstructured":"Pereira MV, Galvani RG, Gon\u00e7alves-Silva T, de Vasconcelo ZFM, Bonomo A. Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer. Front Immunol. 2024;15:1379376.","journal-title":"Front Immunol"},{"key":"2897_CR2","first-page":"223","volume-title":"Biomarkers in cancer detection and monitoring of therapeutics","author":"B Iyshwarya","year":"2024","unstructured":"Iyshwarya B, Veerabathiran R. Shared and distinct aspects of hematopoietic malignancies such as leukemia and lymphoma. In: Biomarkers in cancer detection and monitoring of therapeutics. Amsterdam: Elsevier; 2024. p. 223\u201334."},{"key":"2897_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.52711\/2321-5836.2024.00018","volume":"16","author":"AS Mane","year":"2024","unstructured":"Mane AS. Non-hodgkins lymphoma: a comprehensive guide. Res J Pharmacol Pharmacodyn. 2024;16:99\u2013106.","journal-title":"Res J Pharmacol Pharmacodyn"},{"key":"2897_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12672-024-01698-3","volume":"16","author":"A Berhan","year":"2025","unstructured":"Berhan A, Almaw A, Damtie S, Solomon Y. Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review. Discov Oncol. 2025;16:1\u201315.","journal-title":"Discov Oncol"},{"key":"2897_CR5","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.3390\/cancers15082285","volume":"15","author":"KS Kurz","year":"2023","unstructured":"Kurz KS, Ott M, Kalmbach S, Steinlein S, Kalla C, Horn H, et al. Large B-Cell lymphomas in the 5th edition of the WHO-classification of haematolymphoid neoplasms\u2014updated classification and new concepts. Cancers. 2023;15:2285.","journal-title":"Cancers"},{"key":"2897_CR6","doi-asserted-by":"publisher","first-page":"204062072198957","DOI":"10.1177\/2040620721989579","volume":"12","author":"M Candelaria","year":"2021","unstructured":"Candelaria M, Due\u00f1as-Gonzalez A. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Ther Adv Hematol. 2021;12:2040620721989579.","journal-title":"Ther Adv Hematol"},{"key":"2897_CR7","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/cancers16122243","volume":"16","author":"F D\u2019Al\u00f2","year":"2024","unstructured":"D\u2019Al\u00f2 F, Bellesi S, Maiolo E, Alma E, Bellisario F, Malafronte R, et al. Novel targets and advanced therapies in diffuse large B cell lymphomas. Cancers. 2024;16:2243.","journal-title":"Cancers"},{"key":"2897_CR8","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/biomedicines10092153","volume":"10","author":"F Jardin","year":"2022","unstructured":"Jardin F. NFkB pathway and Hodgkin lymphoma. Biomedicines. 2022;10:2153.","journal-title":"Biomedicines"},{"key":"2897_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/pharmacia.72.e146759","volume":"72","author":"M Moneva-Sakelarieva","year":"2025","unstructured":"Moneva-Sakelarieva M, Kobakova Y, Konstantinov S, Momekov G, Ivanova S, Atanasova V, et al. The role of the transcription factor NF-kB in the pathogenesis of inflammation and carcinogenesis. Modulation capabilities. Pharmacia. 2025;72:1\u201313.","journal-title":"Pharmacia"},{"key":"2897_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al. NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9:53.","journal-title":"Signal Transduct Target Ther"},{"key":"2897_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41417-024-00811-6","volume":"31","author":"A Khan","year":"2024","unstructured":"Khan A, Zhang Y, Ma N, Shi J, Hou Y. NF-\u03baB role on tumor proliferation, migration, invasion and immune escape. Cancer Gene Ther. 2024;31:1599\u2013610.","journal-title":"Cancer Gene Ther"},{"key":"2897_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.it.2022.07.004","volume":"43","author":"D Capece","year":"2022","unstructured":"Capece D, Verzella D, Flati I, Arboretto P, Cornice J, Franzoso G. NF-\u03baB: blending metabolism, immunity, and inflammation. Trends Immunol. 2022;43:757\u201375.","journal-title":"Trends Immunol"},{"key":"2897_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s40364-024-00710-w","volume":"12","author":"A Sobczy\u0144ska-Konefa\u0142","year":"2024","unstructured":"Sobczy\u0144ska-Konefa\u0142 A, Jasek M, Karabon L, Jasku\u0142a E. Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies. Biomark Res. 2024;12:162.","journal-title":"Biomark Res"},{"key":"2897_CR14","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.3390\/ijms22126247","volume":"22","author":"L Sadeghi","year":"2021","unstructured":"Sadeghi L, Wright AP. Migration and adhesion of B-lymphocytes to specific microenvironments in mantle cell lymphoma: interplay between signaling pathways and the epigenetic landscape. Int J Mol Sci. 2021;22:6247.","journal-title":"Int J Mol Sci"},{"key":"2897_CR15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/mco2.104","volume":"2","author":"T Zhang","year":"2021","unstructured":"Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-\u03baB signaling in inflammation and cancer. MedComm. 2021;2:618\u201353.","journal-title":"MedComm"},{"key":"2897_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.114977","volume":"198","author":"Y-Y Zhang","year":"2022","unstructured":"Zhang Y-Y, Peng J, Luo X-J. Post-translational modification of MALT1 and its role in B cell-and T cell-related diseases. Biochem Pharmacol. 2022;198: 114977.","journal-title":"Biochem Pharmacol"},{"key":"2897_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110611","volume":"105","author":"FA Mazi","year":"2023","unstructured":"Mazi FA, Cakiroglu E, Uysal M, Kalyoncu M, Demirci D, Sozeri PYG, et al. The paracaspase MALT1 is a downstream target of Smad3 and potentiates the crosstalk between TGF-\u03b2 and NF-kB signaling pathways in cancer cells. Cell Signal. 2023;105: 110611.","journal-title":"Cell Signal"},{"key":"2897_CR18","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1038\/onc.2015.493","volume":"35","author":"M Bognar","year":"2016","unstructured":"Bognar M, Vincendeau M, Erdmann T, Seeholzer T, Grau M, Linnemann J, et al. Oncogenic CARMA1 couples NF-\u03baB and \u03b2-catenin signaling in diffuse large B-cell lymphomas. Oncogene. 2016;35:4269\u201381.","journal-title":"Oncogene"},{"key":"2897_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fonc.2018.00498","volume":"8","author":"A Thys","year":"2018","unstructured":"Thys A, Douanne T, Bid\u00e8re N. Post-translational modifications of the CARMA1-BCL10-MALT1 complex in lymphocytes and activated B-cell like subtype of diffuse large B-cell lymphoma. Front Oncol. 2018;8:498.","journal-title":"Front Oncol"},{"key":"2897_CR20","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1021\/acs.jmedchem.4c02873","volume":"68","author":"R-Y Zhang","year":"2025","unstructured":"Zhang R-Y, Wang Z-X, Zhang M-Y, Wang Y-F, Zhou S-L, Xu J-L, et al. MALT1 inhibitors and degraders: strategies for NF-\u03baB-driven malignancies. J Med Chem. 2025;68:5075\u201396.","journal-title":"J Med Chem"},{"key":"2897_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164573","volume":"135","author":"H Kang","year":"2025","unstructured":"Kang H, Maurer LM, Cheng J, Smyers M, Klei LR, Hu D, et al. A small-molecule inhibitor of BCL10\u2013MALT1 interaction abrogates progression of diffuse large B cell lymphoma. J Clin Investig. 2025;135: e164573. https:\/\/doi.org\/10.1172\/JCI164573.","journal-title":"J Clin Investig"},{"key":"2897_CR22","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41598-018-19822-z","volume":"8","author":"A Abd-Ellah","year":"2018","unstructured":"Abd-Ellah A, Voogdt C, Krappmann D, M\u00f6ller P, Marienfeld RB. GSK3\u03b2 modulates NF-\u03baB activation and RelB degradation through site-specific phosphorylation of BCL10. Sci Rep. 2018;8:1352.","journal-title":"Sci Rep"},{"key":"2897_CR23","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/bloodadvances.2023012394","volume":"8","author":"Y Yao","year":"2024","unstructured":"Yao Y, Yuan M, Shi M, Li W, Sha Y, Zhang Y, et al. Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-\u03baB and inducing immunogenic cell death. Blood Adv. 2024;8:4003\u201316.","journal-title":"Blood Adv"},{"key":"2897_CR24","doi-asserted-by":"publisher","first-page":"1412347","DOI":"10.3389\/fimmu.2024.1412347","volume":"15","author":"BN Moud","year":"2024","unstructured":"Moud BN, Ober F, O\u2019Neill TJ, Krappmann D. MALT1 substrate cleavage: what is it good for? Front Immunol. 2024;15:1412347.","journal-title":"Front Immunol"},{"key":"2897_CR25","unstructured":"Pack A. Computational systems biology modelling of NF-\u03baB signalling in B cell lymphoma. University of Brighton. 2024."},{"key":"2897_CR26","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1038\/s41467-018-06573-8","volume":"9","author":"F Schlauderer","year":"2018","unstructured":"Schlauderer F, Seeholzer T, Desfosses A, Gehring T, Strauss M, Hopfner K-P, et al. Molecular architecture and regulation of BCL10-MALT1 filaments. Nat Commun. 2018;9:4041.","journal-title":"Nat Commun"},{"key":"2897_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-018-0087-2","volume":"19","author":"J Ruland","year":"2019","unstructured":"Ruland J, Hartjes L. CARD\u2013BCL-10\u2013MALT1 signalling in protective and pathological immunity. Nat Rev Immunol. 2019;19:118\u201334.","journal-title":"Nat Rev Immunol"},{"key":"2897_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.911811","volume":"10","author":"T Qi","year":"2022","unstructured":"Qi T, Luo Y, Cui W, Zhou Y, Ma X, Wang D, et al. Crosstalk between the CBM complex\/NF-\u03baB and MAPK\/P27 signaling pathways of regulatory T cells contributes to the tumor microenvironment. Front Cell Dev Biol. 2022;10: 911811.","journal-title":"Front Cell Dev Biol"},{"key":"2897_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaci.2014.06.015","volume":"134","author":"SE Turvey","year":"2014","unstructured":"Turvey SE, Durandy A, Fischer A, Fung S-Y, Geha RS, Gewies A, et al. The CARD11-BCL10-MALT1 (CBM) signalosome complex: stepping into the limelight of human primary immunodeficiency. J Allergy Clin Immunol. 2014;134:276\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2014.06.015.","journal-title":"J Allergy Clin Immunol"},{"key":"2897_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/cmi.2017.77","volume":"15","author":"L Isra\u00ebl","year":"2018","unstructured":"Isra\u00ebl L, Bornancin F. Ways and waves of MALT1 paracaspase activation. Cell Mol Immunol. 2018;15:8\u201311.","journal-title":"Cell Mol Immunol"},{"key":"2897_CR31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/biom15030420","volume":"15","author":"P Sun","year":"2025","unstructured":"Sun P, Yang L, Yu K, Wang J, Chao J. Scaffold proteins in fibrotic diseases of visceral organs. Biomolecules. 2025;15:420.","journal-title":"Biomolecules"},{"key":"2897_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40364-024-00630-9","volume":"12","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Xu J, Liu S, Lv Y, Zhang R, Zhou X, et al. Infiltrating Treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy. Biomark Res. 2024;12:97.","journal-title":"Biomark Res"},{"key":"2897_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13353-023-00804-5","volume":"65","author":"HA Almasmoum","year":"2024","unstructured":"Almasmoum HA. Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications. J Appl Genet. 2024;65:57\u201372.","journal-title":"J Appl Genet"},{"key":"2897_CR34","doi-asserted-by":"publisher","first-page":"7048","DOI":"10.3390\/cimb46070420","volume":"46","author":"E Koumpis","year":"2024","unstructured":"Koumpis E, Papoudou-Bai A, Papathanasiou K, Kolettas E, Kanavaros P, Hatzimichael E. Unraveling the immune microenvironment in diffuse large B-cell lymphoma: prognostic and potential therapeutic implications. Curr Issues Mol Biol. 2024;46:7048\u201364.","journal-title":"Curr Issues Mol Biol"},{"key":"2897_CR35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1158\/1535-7163.MCT-23-0518","volume":"23","author":"JP Plotnik","year":"2024","unstructured":"Plotnik JP, Richardson AE, Yang H, Rojas E, Bontcheva V, Dowell C, et al. Inhibition of MALT1 and BCL2 induces synergistic antitumor activity in models of B-cell lymphoma. Mol Cancer Ther. 2024;23:949\u201360.","journal-title":"Mol Cancer Ther"},{"key":"2897_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-024-01073-x","volume":"25","author":"SE Degn","year":"2024","unstructured":"Degn SE, Tolar P. Towards a unifying model for B-cell receptor triggering. Nat Rev Immunol. 2024;25:77\u201391.","journal-title":"Nat Rev Immunol"},{"key":"2897_CR37","doi-asserted-by":"publisher","first-page":"1339620","DOI":"10.3389\/fonc.2024.1339620","volume":"14","author":"VK Schmid","year":"2024","unstructured":"Schmid VK, Hobeika E. B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia. Front Oncol. 2024;14:1339620.","journal-title":"Front Oncol"},{"key":"2897_CR38","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41586-024-07018-7","volume":"626","author":"J Garcia","year":"2024","unstructured":"Garcia J, Daniels J, Lee Y, Zhu I, Cheng K, Liu Q, et al. Naturally occurring T cell mutations enhance engineered T cell therapies. Nature. 2024;626:626\u201334.","journal-title":"Nature"},{"key":"2897_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/9781119423195.ch26","volume-title":"Morson and Dawson\u2019s gastrointestinal pathology","author":"L de Leval","year":"2024","unstructured":"de Leval L, Bhagat G. Lymphoid tumours of the small intestine. In: Morson and Dawson\u2019s gastrointestinal pathology. New York: Wiley; 2024. p. 579\u2013605."},{"key":"2897_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/9781394180486.ch8","volume-title":"Molecular hematology","author":"G Insuasti-Beltran","year":"2024","unstructured":"Insuasti-Beltran G, McCall CM, Hsi ED. Lymphoma genetics. In: Molecular hematology. New York: Wiley; 2024. p. 113\u201325."},{"key":"2897_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-4188-0_1","volume":"2865","author":"MA Weniger","year":"2025","unstructured":"Weniger MA, Seifert M, K\u00fcppers R. B cell differentiation and the origin and pathogenesis of human B cell lymphomas. Methods Mol Biol. 2025;2865:1\u201330.","journal-title":"Methods Mol Biol"},{"key":"2897_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005442","volume":"10","author":"TR Mempel","year":"2022","unstructured":"Mempel TR, Krappmann D. Combining precision oncology and immunotherapy by targeting the MALT1 protease. J Immunother Cancer. 2022;10: e005442. https:\/\/doi.org\/10.1136\/jitc-2022-005442.","journal-title":"J Immunother Cancer"},{"key":"2897_CR43","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2174\/157339505774479248","volume":"1","author":"J Ruland","year":"2005","unstructured":"Ruland J. Molecular functions of BCL10 and MALT1 in normal and neoplastic lymphocytes. Curr Immunol Rev. 2005;1:287\u201396.","journal-title":"Curr Immunol Rev"},{"key":"2897_CR44","first-page":"177","volume":"1","author":"Y Gao","year":"2024","unstructured":"Gao Y, Schedin-Weiss S, Tjernberg LO. A closer look at pathogenic amyloid-\u03b2 in Alzheimer\u2019s disease using cryo-electron microscopy: a narrative review. Adv Technol Neurosci. 2024;1:177\u201387.","journal-title":"Adv Technol Neurosci"},{"key":"2897_CR45","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3389\/fimmu.2018.01539","volume":"9","author":"T Gehring","year":"2018","unstructured":"Gehring T, Seeholzer T, Krappmann D. BCL10\u2014bridging CARDs to immune activation. Front Immunol. 2018;9:1539.","journal-title":"Front Immunol"},{"key":"2897_CR46","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.3390\/cancers13184510","volume":"13","author":"J Silke","year":"2021","unstructured":"Silke J, O\u2019Reilly LA. NF-\u03baB and pancreatic cancer: chapter and verse. Cancers. 2021;13:4510.","journal-title":"Cancers"},{"key":"2897_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12964-023-01433-5","volume":"22","author":"M Pakjoo","year":"2024","unstructured":"Pakjoo M, Ahmadi SE, Zahedi M, Jaafari N, Khademi R, Amini A, et al. Interplay between proteasome inhibitors and NF-\u03baB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors. Cell Communication and Signaling. 2024;22:105.","journal-title":"Cell Communication and Signaling"},{"key":"2897_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cells5020015","volume":"5","author":"MH Park","year":"2016","unstructured":"Park MH, Hong JT. Roles of NF-\u03baB in cancer and inflammatory diseases and their therapeutic approaches. Cells. 2016;5:15.","journal-title":"Cells"},{"key":"2897_CR49","doi-asserted-by":"publisher","first-page":"11384","DOI":"10.3390\/ijms252111384","volume":"25","author":"R Masnikosa","year":"2024","unstructured":"Masnikosa R, Cvetkovi\u0107 Z, Piri\u0107 D. Tumor biology hides novel therapeutic approaches to diffuse large B-cell lymphoma: a narrative review. Int J Mol Sci. 2024;25:11384.","journal-title":"Int J Mol Sci"},{"key":"2897_CR50","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/s41375-021-01285-3","volume":"35","author":"MY He","year":"2021","unstructured":"He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 2021;35:2151\u201365.","journal-title":"Leukemia"},{"key":"2897_CR51","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10:1367\u2013401.","journal-title":"Genes Dis"},{"key":"2897_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discovery. 2023;22:213\u201334.","journal-title":"Nat Rev Drug Discovery"},{"key":"2897_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.fsi.2024.110100","volume":"157","author":"G Shen","year":"2025","unstructured":"Shen G, Wang G, Chen J, Guo Y, Zhang W, Xu C, et al. MALT1 promotes the antibacterial immune response by activating NF-\u03baB signaling and enhancing hemocyte phagocytosis in the Chinese mitten crab. Fish Shellfish Immunol. 2025;157: 110100.","journal-title":"Fish Shellfish Immunol"},{"key":"2897_CR54","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2024.2407376","author":"MM Alshehri","year":"2024","unstructured":"Alshehri MM, Alshammari MK, Alghazwni MK, Ejaz SA, Aziz M, Alshehri AM, et al. In silico study of some plant compounds as potential anticancer agents targeting MALT1 allosteric domain. J Biomol Struct Dyn. 2024. https:\/\/doi.org\/10.1080\/07391102.2024.2407376.","journal-title":"J Biomol Struct Dyn"},{"key":"2897_CR55","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.3390\/ijms26062534","volume":"26","author":"F Lospinoso Severini","year":"2025","unstructured":"Lospinoso Severini F, Falco G, Notarangelo T. Role of soluble cytokine receptors in gastric cancer development and chemoresistance. Int J Mol Sci. 2025;26:2534.","journal-title":"Int J Mol Sci"},{"key":"2897_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.70125","volume":"39","author":"M Wang","year":"2025","unstructured":"Wang M, Wang X. Chemoprotective potential of cyanidin-3-glucoside against 1,2-dimethylhydrazine-induced colorectal cancer: modulation of NF-\u03baB and Bcl-2\/Bax\/Caspase pathway. J Biochem Mol Toxicol. 2025;39: e70125.","journal-title":"J Biochem Mol Toxicol"},{"key":"2897_CR57","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1021\/acs.jmedchem.3c02031","volume":"67","author":"X Liang","year":"2024","unstructured":"Liang X, Yu H, Liang R, Feng Z, Saidahmatov A, Sun C, et al. Development of potent MALT1 inhibitors featuring a novel \u201c2-thioxo-2,3-dihydrothiazolo [4,5-d] pyrimidin-7(6H)-one\u201d scaffold for the treatment of B cell lymphoma. J Med Chem. 2024;67:2884\u2013906.","journal-title":"J Med Chem"},{"key":"2897_CR58","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/biomedicines10020344","volume":"10","author":"B Gomez Solsona","year":"2022","unstructured":"Gomez Solsona B, Schmitt A, Schulze-Osthoff K, Hailfinger S. The paracaspase MALT1 in cancer. Biomedicines. 2022;10:344.","journal-title":"Biomedicines"},{"key":"2897_CR59","doi-asserted-by":"publisher","first-page":"9981","DOI":"10.3390\/ijms23179981","volume":"23","author":"C O\u2019Connell","year":"2022","unstructured":"O\u2019Connell C, VandenHeuvel S, Kamat A, Raghavan S, Godin B. The proteolytic landscape of ovarian cancer: applications in nanomedicine. Int J Mol Sci. 2022;23:9981.","journal-title":"Int J Mol Sci"},{"key":"2897_CR60","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood.2023021299","volume":"142","author":"N Wimberger","year":"2023","unstructured":"Wimberger N, Ober F, Avar G, Grau M, Xu W, Lenz G, et al. Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas. Blood. 2023;142:1985\u20132001.","journal-title":"Blood"},{"issue":"5","key":"2897_CR61","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-024-01100-5","volume":"24","author":"A Mulvey","year":"2025","unstructured":"Mulvey A, Trueb L, Coukos G, Arber C. Novel strategies to manage CAR-T cell toxicity. Nat Rev Drug Discovery. 2025;24(5):379\u201397.","journal-title":"Nat Rev Drug Discovery"},{"key":"2897_CR62","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/med.21799","volume":"41","author":"X Liang","year":"2021","unstructured":"Liang X, Cao Y, Li C, Yu H, Yang C, Liu H. MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies. Med Res Rev. 2021;41:2388\u2013422.","journal-title":"Med Res Rev"},{"key":"2897_CR63","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1515\/hsz-2016-0216","volume":"397","author":"I Meininger","year":"2016","unstructured":"Meininger I, Krappmann D. Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome. Biol Chem. 2016;397:1315\u201333.","journal-title":"Biol Chem"},{"key":"2897_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.875320","volume":"13","author":"S Biswas","year":"2022","unstructured":"Biswas S, Chalishazar A, Helou Y, DiSpirito J, DeChristopher B, Chatterjee D, et al. Pharmacological inhibition of MALT1 ameliorates autoimmune pathogenesis and can be uncoupled from effects on regulatory T-cells. Front Immunol. 2022;13: 875320.","journal-title":"Front Immunol"},{"key":"2897_CR65","volume-title":"MyD88 Co-stimulation in CD8+ T cells improves tumor immunotherapy in allogeneic and syngeneic models","author":"NG Ciavattone","year":"2021","unstructured":"Ciavattone NG. MyD88 Co-stimulation in CD8+ T cells improves tumor immunotherapy in allogeneic and syngeneic models. Baltimore: University of Maryland; 2021."},{"key":"2897_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117177","volume":"178","author":"NK Bhol","year":"2024","unstructured":"Bhol NK, Bhanjadeo MM, Singh AK, Dash UC, Ojha RR, Majhi S, et al. The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed Pharmacother. 2024;178: 117177.","journal-title":"Biomed Pharmacother"},{"key":"2897_CR67","doi-asserted-by":"publisher","first-page":"9522","DOI":"10.3390\/ijms25179522","volume":"25","author":"A D\u0105browska","year":"2024","unstructured":"D\u0105browska A, Wilczy\u0144ski B, Mastalerz J, Kucharczyk J, Kulbacka J, Szewczyk A, et al. The impact of liver failure on the immune system. Int J Mol Sci. 2024;25:9522.","journal-title":"Int J Mol Sci"},{"key":"2897_CR68","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3389\/fimmu.2019.01898","volume":"10","author":"A Demeyer","year":"2019","unstructured":"Demeyer A, Skordos I, Driege Y, Kreike M, Hochepied T, Baens M, et al. MALT1 proteolytic activity suppresses autoimmunity in a T cell intrinsic manner. Front Immunol. 2019;10:1898.","journal-title":"Front Immunol"},{"key":"2897_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101557","volume":"23","author":"A Demeyer","year":"2020","unstructured":"Demeyer A, Driege Y, Skordos I, Coudenys J, Lemeire K, Elewaut D, et al. Long-term MALT1 inhibition in adult mice without severe systemic autoimmunity. Iscience. 2020;23: 101557.","journal-title":"Iscience"},{"key":"2897_CR70","doi-asserted-by":"publisher","first-page":"1443297","DOI":"10.3389\/fimmu.2024.1443297","volume":"15","author":"C Mazzuca","year":"2024","unstructured":"Mazzuca C, Vitiello L, Travaglini S, Maurizi F, Finamore P, Santangelo S, et al. Immunological and homeostatic pathways of alpha-1 antitrypsin: a new therapeutic potential. Front Immunol. 2024;15:1443297.","journal-title":"Front Immunol"},{"key":"2897_CR71","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1215-2","volume":"570","author":"M Di Pilato","year":"2019","unstructured":"Di Pilato M, Kim EY, Cadilha BL, Pr\u00fc\u00dfmann JN, Nasrallah MN, Seruggia D, et al. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature. 2019;570:112\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1215-2.","journal-title":"Nature"},{"key":"2897_CR72","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4049\/jimmunol.178.2.953","volume":"178","author":"PJ Jost","year":"2007","unstructured":"Jost PJ, Weiss S, Ferch U, Gross O, Mak TW, Peschel C, et al. Bcl10\/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selection. J Immunol. 2007;178:953\u201360. https:\/\/doi.org\/10.4049\/jimmunol.178.2.953.","journal-title":"J Immunol"},{"key":"2897_CR73","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.4049\/jimmunol.1900327","volume":"203","author":"K Martin","year":"2019","unstructured":"Martin K, Touil R, Kolb Y, Cvijetic G, Murakami K, Israel L, et al. Malt1 protease deficiency in mice disrupts immune homeostasis at environmental barriers and drives systemic T cell-mediated autoimmunity. J Immunol. 2019;203:2791\u2013806. https:\/\/doi.org\/10.4049\/jimmunol.1900327.","journal-title":"J Immunol"},{"key":"2897_CR74","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1038\/s41467-019-10203-2","volume":"10","author":"M Rosenbaum","year":"2019","unstructured":"Rosenbaum M, Gewies A, Pechloff K, Heuser C, Engleitner T, Gehring T, et al. Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. Nat Commun. 2019;10:2352. https:\/\/doi.org\/10.1038\/s41467-019-10203-2.","journal-title":"Nat Commun"},{"key":"2897_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107622","volume":"148","author":"D Feng","year":"2025","unstructured":"Feng D, Bai S, Liang D, Chen X, Xia Z, Liang Y, et al. RCHOP plus BTK inhibitor improves clinical outcomes in double expressor diffuse large B-cell lymphoma, unlike RCHOP plus lenalidomide. Leukemia Res. 2025;148: 107622. https:\/\/doi.org\/10.1016\/j.leukres.2024.107622.","journal-title":"Leukemia Res"},{"key":"2897_CR76","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jaci.2022.06.023","volume":"150","author":"SB DeVore","year":"2022","unstructured":"DeVore SB, Khurana Hershey GK. The role of the CBM complex in allergic inflammation and disease. J Allergy Clin Immunol. 2022;150:1011\u201330. https:\/\/doi.org\/10.1016\/j.jaci.2022.06.023.","journal-title":"J Allergy Clin Immunol"},{"key":"2897_CR77","unstructured":"Chalfant RA. The genetics of psoriasis\u2014an emphasis on CARD14. Icahn School of Medicine at Mount Sinai. 2025."},{"key":"2897_CR78","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1042\/BCJ20220094","volume":"482","author":"B Kobe","year":"2025","unstructured":"Kobe B, Nanson JD, Hoad M, Blumenthal A, Gambin Y, Sierecki E, et al. Signalling by co-operative higher-order assembly formation: linking evidence at molecular and cellular levels. Biochemical Journal. 2025;482:275\u201394.","journal-title":"Biochemical Journal"},{"key":"2897_CR79","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.celrep.2019.09.040","volume":"29","author":"T Gehring","year":"2019","unstructured":"Gehring T, Erdmann T, Rahm M, Gra\u00df C, Flatley A, O\u2019Neill TJ, et al. MALT1 phosphorylation controls activation of T lymphocytes and survival of ABC-DLBCL tumor cells. Cell Rep. 2019;29:873-888.e10.","journal-title":"Cell Rep"},{"key":"2897_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102568","volume":"117","author":"TJ O\u2019Neill","year":"2023","unstructured":"O\u2019Neill TJ, Tofaute MJ, Krappmann D. Function and targeting of MALT1 paracaspase in cancer. Cancer Treat Rev. 2023;117: 102568.","journal-title":"Cancer Treat Rev"},{"key":"2897_CR81","doi-asserted-by":"publisher","first-page":"10800","DOI":"10.3390\/ijms221910800","volume":"22","author":"S Gavali","year":"2021","unstructured":"Gavali S, Liu J, Li X, Paolino M. Ubiquitination in T-cell activation and checkpoint inhibition: new avenues for targeted cancer immunotherapy. Int J Mol Sci. 2021;22:10800.","journal-title":"Int J Mol Sci"},{"key":"2897_CR82","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41418-020-00676-w","volume":"28","author":"AS Jahan","year":"2021","unstructured":"Jahan AS, Elb\u00e6k CR, Damgaard RB. Met1-linked ubiquitin signalling in health and disease: inflammation, immunity, cancer, and beyond. Cell Death Differ. 2021;28:473\u201392.","journal-title":"Cell Death Differ"},{"key":"2897_CR83","doi-asserted-by":"crossref","unstructured":"Kang H. Discovery of novel small molecule inhibitors of Bcl10-MALT1 interaction for the treatment of aggressive diffuse large B-cell lymphoma. University of Pittsburgh. 2020.","DOI":"10.1158\/1538-7445.AM2020-3404"},{"key":"2897_CR84","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/13543776.2021.1951703","volume":"31","author":"I Hamp","year":"2021","unstructured":"Hamp I, O\u2019Neill TJ, Plettenburg O, Krappmann D. A patent review of MALT1 inhibitors (2013-present). Expert Opin Ther Pat. 2021;31:1079\u201396.","journal-title":"Expert Opin Ther Pat"},{"key":"2897_CR85","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021109823","volume":"41","author":"JR Kovalski","year":"2022","unstructured":"Kovalski JR, Kuzuoglu-Ozturk D, Ruggero D. Protein synthesis control in cancer: selectivity and therapeutic targeting. EMBO J. 2022;41: e109823.","journal-title":"EMBO J"},{"key":"2897_CR86","first-page":"18","volume":"2024","author":"HA Kang","year":"2026","unstructured":"Kang HA, Wang B, Barner J, Ataga K, Mignacca R, Chang A. Effects of the CDC\u2019s 2016 opioid guidelines on pediatric and adult patients with sickle cell disease. Oncology. 2026;2024:18.","journal-title":"Oncology"},{"key":"2897_CR87","volume-title":"Pediatric blood & cancer","author":"L Maurer","year":"2022","unstructured":"Maurer L, Kang H, Smyers M, Klei L, Cheng J, Trotta M, et al. Blocking the BCL10\u2013MALT1 interaction in diffuse large B-cell lymphoma. In: Pediatric blood & cancer. Hoboken, NJ: Wiley; 2022."},{"key":"2897_CR88","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/v15122361","volume":"15","author":"H Wang","year":"2023","unstructured":"Wang H, Xiao B, Chen S, He J, Li C. Identification of an ortholog of MALT1 from shrimp that induces NF-\u03baB-mediated antiviral immunity. Viruses. 2023;15:2361.","journal-title":"Viruses"},{"key":"2897_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107954","volume":"300","author":"W Zheng","year":"2024","unstructured":"Zheng W, Guo J, Ma S, Sun R, Song Y, Chen Y, et al. The NEDD4-binding protein N4BP1 degrades mRNA substrates through the coding sequence independent of nonsense-mediated decay. J Biol Chem. 2024;300: 107954.","journal-title":"J Biol Chem"},{"key":"2897_CR90","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1080\/10428194.2021.1999444","volume":"63","author":"MR Seshadri","year":"2022","unstructured":"Seshadri MR, Melnick AM. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Leuk Lymphoma. 2022;63:789\u201398.","journal-title":"Leuk Lymphoma"},{"key":"2897_CR91","unstructured":"Sackey B. Elucidation of the role of DNA-damage response genes in the tumor microenvironment and molecular characterization of a \u201ctropical\u201d chronic lymphocytic leukemia cohort. Universit\u00e4t zu K\u00f6ln. 2023."},{"issue":"23","key":"2897_CR92","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/blood.2024025755","volume":"145","author":"M Garcia-Lacarte","year":"2025","unstructured":"Garcia-Lacarte M, Grijalba SC, Melchor J, Pascual M, Goni E, Clemente-Larramendi I, et al. IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy. Blood. 2025;145(23):2746\u201361.","journal-title":"Blood"},{"key":"2897_CR93","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41408-025-01214-y","volume":"15","author":"CA Coughlin","year":"2025","unstructured":"Coughlin CA, Chahar D, Lekakis M, Youssfi AA, Li L, Roberts E, et al. Bruton\u2019s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax. Blood Cancer J. 2025;15:9.","journal-title":"Blood Cancer J"},{"key":"2897_CR94","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240272","volume":"222","author":"BM Bauman","year":"2025","unstructured":"Bauman BM, Stinson JR, Kallarakal MA, Huang LH, Frank AM, Sukumar G, et al. Dominant interfering CARD11 variants disrupt JNK signaling to promote GATA3 expression in T cells. J Exp Med. 2025;222: e20240272.","journal-title":"J Exp Med"},{"key":"2897_CR95","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-981-97-7288-9_2","volume-title":"Ubiquitination in immune system and immune response","author":"K-Q Fan","year":"2024","unstructured":"Fan K-Q, Li Y-Y, Jin J. Ubiquitination in the T cell metabolism-based immunotherapy in diseases. In: Ubiquitination in immune system and immune response. Singapore: Springer; 2024. p. 19\u201334."},{"key":"2897_CR96","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41388-019-1088-8","volume":"39","author":"H Mukhopadhyay","year":"2020","unstructured":"Mukhopadhyay H, Lee NY. Multifaceted roles of TAK1 signaling in cancer. Oncogene. 2020;39:1402\u201313.","journal-title":"Oncogene"},{"key":"2897_CR97","first-page":"788","volume":"137","author":"L Fontan","year":"2021","unstructured":"Fontan L, Goldstein R, Casalena G, Durant M, Teater MR, Wilson J, et al. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood J Am Soc Hematol. 2021;137:788\u2013800.","journal-title":"Blood J Am Soc Hematol"},{"key":"2897_CR98","unstructured":"Hansen J. Autochthonous mouse models as tools to study diffuse large B-cell lymphoma. Universit\u00e4t zu K\u00f6ln. 2024."},{"key":"2897_CR99","doi-asserted-by":"publisher","first-page":"1476030","DOI":"10.3389\/fimmu.2024.1476030","volume":"15","author":"Y Cao","year":"2024","unstructured":"Cao Y, Yi Y, Han C, Shi B. NF-\u03baB signaling pathway in tumor microenvironment. Front Immunol. 2024;15:1476030.","journal-title":"Front Immunol"},{"key":"2897_CR100","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/B978-0-443-18716-2.00008-9","volume-title":"Protein misfolding in neurodegenerative diseases","author":"P Kumar","year":"2025","unstructured":"Kumar P. Advances in developing novel therapeutics, strategies, approaches, and use of emerging techniques. In: Protein misfolding in neurodegenerative diseases. Amsterdam: Elsevier; 2025. p. 291\u2013318."},{"key":"2897_CR101","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood-2024-198624","volume":"144","author":"CS Diefenbach","year":"2024","unstructured":"Diefenbach CS, Zelenetz AD, Herbaux C, Tani M, Houot R, Bastos-Oreiro M, et al. Final analysis of the safety and efficacy of venetoclax in combination with Pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double\/triple hit lymphoma. Blood. 2024;144:577. https:\/\/doi.org\/10.1182\/blood-2024-198624.","journal-title":"Blood"},{"key":"2897_CR102","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s43018-025-00930-5","volume":"6","author":"Y Tao","year":"2025","unstructured":"Tao Y, Tian C, Qi S, Jia Z, Xu Z, Meng J, et al. Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors. Nat Cancer. 2025;6:702\u201317.","journal-title":"Nat Cancer"},{"key":"2897_CR103","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12032-023-02289-y","volume":"41","author":"R Singh","year":"2024","unstructured":"Singh R, Srivastava P, Manna PP. Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition. Med Oncol. 2024;41:59.","journal-title":"Med Oncol"},{"key":"2897_CR104","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","volume":"21","author":"S Kumagai","year":"2024","unstructured":"Kumagai S, Itahashi K, Nishikawa H. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nat Rev Clin Oncol. 2024;21:337\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"2897_CR105","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.26.614808","author":"JH Azambuja","year":"2024","unstructured":"Azambuja JH, Yerneni SS, Maurer LM, Crentsil HE, Debom GN, Klei L, et al. MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.09.26.614808.","journal-title":"bioRxiv"},{"key":"2897_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122684","volume":"348","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Lin M, Zeng C, Zhang J. NF-\u03baB signaling in therapy resistance of breast cancer: mechanisms, approaches, and challenges. Life Sci. 2024;348: 122684.","journal-title":"Life Sci"},{"key":"2897_CR107","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00018-023-05098-8","volume":"81","author":"N Ebrahimi","year":"2024","unstructured":"Ebrahimi N, Abdulwahid A-HRR, Mansouri A, Karimi N, Bostani RJ, Beiranvand S, et al. Targeting the NF-\u03baB pathway as a potential regulator of immune checkpoints in cancer immunotherapy. Cell Mol Life Sci. 2024;81:106.","journal-title":"Cell Mol Life Sci"},{"key":"2897_CR108","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2174\/1389557523666230519162803","volume":"24","author":"K Choi","year":"2024","unstructured":"Choi K. Structure-property relationships reported for the new drugs approved in 2022. Mini Rev Med Chem. 2024;24:330\u201340.","journal-title":"Mini Rev Med Chem"},{"key":"2897_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150029","volume":"717","author":"B-J Kuo","year":"2024","unstructured":"Kuo B-J, Lin S-C, Tu Y-F, Huang P-H, Lo Y-C. Study of individual domains contributing to MALT1 dimerization in BCL10-independent and dependent assembly. Biochem Biophys Res Commun. 2024;717: 150029.","journal-title":"Biochem Biophys Res Commun"},{"key":"2897_CR110","doi-asserted-by":"publisher","first-page":"1544085","DOI":"10.3389\/fimmu.2025.1544085","volume":"16","author":"T Mohanty","year":"2025","unstructured":"Mohanty T, Mili\u010devi\u0107 K, G\u00f6thert H, Tillmann A, Padra M, Papareddy P, et al. Balancing inflammation: the specific roles of serum amyloid A proteins in sterile and infectious diseases. Front Immunol. 2025;16:1544085.","journal-title":"Front Immunol"},{"key":"2897_CR111","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1373\/clinchem.2016.255315","volume":"62","author":"M Alcaide","year":"2016","unstructured":"Alcaide M, Yu S, Bushell K, Fornika D, Nielsen JS, Nelson BH, et al. Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma. Clin Chem. 2016;62:1238\u201347. https:\/\/doi.org\/10.1373\/clinchem.2016.255315.","journal-title":"Clin Chem"},{"key":"2897_CR112","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41698-023-00457-x","volume":"7","author":"M Menzel","year":"2023","unstructured":"Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, et al. Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients. NPJ Precis Oncol. 2023;7:106. https:\/\/doi.org\/10.1038\/s41698-023-00457-x.","journal-title":"NPJ Precis Oncol"},{"key":"2897_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103055","volume":"61","author":"S Sangaletti","year":"2020","unstructured":"Sangaletti S, Iannelli F, Zanardi F, Cancila V, Portararo P, Botti L, et al. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. EBioMedicine. 2020;61: 103055. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103055.","journal-title":"EBioMedicine"},{"key":"2897_CR114","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","volume":"36","author":"EM Lauer","year":"2022","unstructured":"Lauer EM, Mutter J, Scherer F. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. Leukemia. 2022;36:2151\u201364. https:\/\/doi.org\/10.1038\/s41375-022-01618-w.","journal-title":"Leukemia"},{"key":"2897_CR115","doi-asserted-by":"publisher","DOI":"10.14440\/jbm.2020.300","volume":"7","author":"G Bondar","year":"2020","unstructured":"Bondar G, Xu W, Elashoff D, Li X, Faure-Kumar E, Bao TM, et al. Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development. J Biol Methods. 2020;7: e123. https:\/\/doi.org\/10.14440\/jbm.2020.300.","journal-title":"J Biol Methods"},{"key":"2897_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100398","volume":"37","author":"Z Wen","year":"2024","unstructured":"Wen Z, Luo D, Wang S, Rong R, Evers BM, Jia L, et al. Deep learning-based H-score quantification of immunohistochemistry-stained images. Mod Pathol. 2024;37: 100398. https:\/\/doi.org\/10.1016\/j.modpat.2023.100398.","journal-title":"Mod Pathol"},{"key":"2897_CR117","unstructured":"Alraddadi AH. Improving therapeutic options and reducing resistance\/relapse in diffuse large B-cell lymphoma. University of Leicester. 2024."},{"key":"2897_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2024.101936","volume":"38","author":"W Sun","year":"2024","unstructured":"Sun W, Zhu C, Li Y, Wu X, Shi X, Liu W. B cell activation and autoantibody production in autoimmune diseases. Best Pract Res Clin Rheumatol. 2024;38: 101936.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2897_CR119","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1182\/blood.2023020211","volume":"142","author":"S Decombis","year":"2023","unstructured":"Decombis S, Bellanger C, Le Bris Y, Madiot C, Jardine J, Santos JC, et al. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma. Blood. 2023;142:1543\u201355.","journal-title":"Blood"},{"key":"2897_CR120","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.4049\/jimmunol.1402254","volume":"194","author":"F Bornancin","year":"2015","unstructured":"Bornancin F, Renner F, Touil R, Sic H, Kolb Y, Touil-Allaoui I, et al. Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation. J Immunol. 2015;194:3723\u201334. https:\/\/doi.org\/10.4049\/jimmunol.1402254.","journal-title":"J Immunol"},{"key":"2897_CR121","unstructured":"Sheikh S. Translational development of MyD88 as a biomarker for selecting patients with lymphoma responsive to histone deacetylase inhibitors. University of Oxford. 2017."},{"key":"2897_CR122","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41590-019-0549-0","volume":"21","author":"L Abeler-D\u00f6rner","year":"2020","unstructured":"Abeler-D\u00f6rner L, Laing AG, Lorenc A, Ushakov DS, Clare S, Speak AO, et al. High-throughput phenotyping reveals expansive genetic and structural underpinnings of immune variation. Nat Immunol. 2020;21:86\u2013100.","journal-title":"Nat Immunol"},{"key":"2897_CR123","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jaci.2013.11.043","volume":"133","author":"WT Shearer","year":"2014","unstructured":"Medical Advisory Committee of the Immune Deficiency Foundation, Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133:961\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"2897_CR124","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3390\/cancers12061396","volume":"12","author":"DG Efremov","year":"2020","unstructured":"Efremov DG, Turkalj S, Laurenti L. Mechanisms of B cell receptor activation and responses to B cell receptor inhibitors in B cell malignancies. Cancers. 2020;12:1396.","journal-title":"Cancers"},{"key":"2897_CR125","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969400.60782.b9","volume":"7","author":"M Kalac","year":"2023","unstructured":"Kalac M, Hertzberg M, Cheah C, Ribrag V, AbrisquetAcosta P, Opat S, et al. P624: phase 1 study of JNJ-67856633, a first-in-human highly selective malt1 inhibitor, in relapsed\/refractory (R\/R) B-cell non-hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL). Hemasphere. 2023;7: e60782b9.","journal-title":"Hemasphere"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02897-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02897-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02897-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:02:45Z","timestamp":1757264565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02897-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":125,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02897-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"350"}}